ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OPNT Opiant Pharmaceuticals Inc

20.65
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Opiant Pharmaceuticals Inc NASDAQ:OPNT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 20.65 18.89 22.41 0 01:00:00

Opiant Pharmaceuticals to Report Fourth Quarter 2020 Financial Results and Host Conference Call and Webcast on March 4, 2021

22/02/2021 9:01pm

GlobeNewswire Inc.


Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Opiant Pharmaceuticals Charts.

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the fourth quarter and year ended December 31, 2020, after the financial markets close on Thursday March 4, 2021.  

The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday March 4, 2021. To access the call, please dial 877-407-0792 in the U.S. or 201-689-8263 outside the U.S. and provide the conference ID number: 13715395. To access the live webcast, please go to the investors section of Opiant’s website at http://ir.opiant.com/. Following the live webcast, an archived version of the call will be available on the website.

Thursday March 4 @ 4:30 pm ET
Domestic:877-407-0792
International:201-689-8263
Conference ID:13715395
Webcast:http://ir.opiant.com/
  

About Opiant Pharmaceuticals, Inc.Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.

For more information visit: www.opiant.com.

Investor Relations Contacts:Ben AtkinsVP of Corporate Communications and Investor Relationsbatkins@opiant.com(310) 598-5410

1 Year Opiant Pharmaceuticals Chart

1 Year Opiant Pharmaceuticals Chart

1 Month Opiant Pharmaceuticals Chart

1 Month Opiant Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock